Skip to content
Screener

TriSalus Life Sciences, Inc. TLSI Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$11.4MBeat by $1.1M
EPS-$0.16Miss by $0.01
Revenue estimate$10.3M
EPS estimate-$0.16
“We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion and adoption of the TriNav platform, and generated clinical evidence that demonstrates and validates the value of our technology. We also wanted to acknowledge the Centers for Medicare and Medicaid Services (.”
Mary Szela

Next report

Nov 12, 2026 (in a month)
Revenue estimate$14.0M
EPS estimate-$0.14

Valuation & ratios

Valuation

as of 10/02/26
See full
Market cap$255.53M+13.4%
Enterprise value$232.06M-1.3%
P/S5.7×+0.1×

FAQ

When did TriSalus Life Sciences, Inc. report Q2 2026 earnings?
TriSalus Life Sciences, Inc. (TLSI) reported Q2 2026 earnings on August 6, 2026 after market close.
What were TriSalus Life Sciences, Inc.'s Q2 2026 revenue and EPS?
TriSalus Life Sciences, Inc. reported revenue of $11.4M and eps of $-0.16 for Q2 2026.
Did TriSalus Life Sciences, Inc. beat estimates in Q2 2026?
Revenue beat the consensus estimate of $10.3M by $1.1M. EPS missed the consensus estimate of $-0.15 by $0.01.
How did TriSalus Life Sciences, Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 1.7% from $11.2M a year earlier and eps grew 40.7% from $-0.27.
Where can I find TriSalus Life Sciences, Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001628280-26-054264) and the 10-Q periodic report (0001628280-26-054275) directly on SEC EDGAR. The filing index links above go to sec.gov.